Wednesday, May 13, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home AI & Quantum Computing

Palantir Shares Face Mounting Pressure as High-Profile Bearish Bets Emerge

Robert Sasse by Robert Sasse
November 22, 2025
in AI & Quantum Computing, Analysis, Insider Trading, Tech & Software
0
Palantir Stock
0
SHARES
99
VIEWS
Share on FacebookShare on Twitter

The investment landscape for Palantir has shifted dramatically in recent days, casting a shadow over the data analytics firm’s previously stellar performance. Two significant developments have converged to unsettle shareholders: a substantial bearish position from famed investor Michael Burry and substantial stock sales by the company’s own chief executive.

CEO’s Substantial Stock Disposal Coincides With Market Jitters

Alex Karp, Palantir’s CEO, executed transactions this week liquidating shares valued at approximately $96 million. While insider selling isn’t uncommon at the company, the timing raises eyebrows among market participants. These disposals occurred during a period of broader weakness across the artificial intelligence sector, amplifying existing investor concerns about valuation sustainability.

Legendary Investor Places Major Bet Against Company

Adding fuel to the bearish sentiment, Michael Burry’s Scion Asset Management has established a significant short position targeting Palantir. Regulatory filings reveal the firm acquired put options covering a nominal value of about $912 million. Burry, celebrated for his early identification of market bubbles and excessive valuations, appears to be signaling that the AI premium embedded in Palantir’s share price is unsustainable. His strategic move suggests anticipation of further contraction before the security can establish a stable valuation foundation.

Strong Operational Performance Contrasts With Valuation Concerns

Paradoxically, Palantir’s business fundamentals appear robust. The company recently reported impressive revenue expansion of 63 percent, primarily driven by widespread adoption of its Artificial Intelligence Platform (AIP) within the U.S. commercial sector. Profit margins continue to improve, and cash flow generation remains healthy.

Should investors sell immediately? Or is it worth buying Palantir?

The central issue lies in the company’s valuation metrics. With a price-to-earnings ratio exceeding 375, the stock appears to be pricing in flawless execution and perpetual growth. Financial analysts caution that this divergence between operational excellence and potentially overheated equity valuation leaves the shares particularly vulnerable to corrective pressures.

Technical Picture Shows Significant Weakness

These fundamental concerns have manifested clearly in the stock’s technical performance. Palantir shares have now retreated approximately 25 percent from their 52-week peak, experiencing elevated volatility throughout the decline. The security alone has surrendered nearly 10 percent of its value during the past seven trading sessions.

As markets open for the week, technical support levels will become critical focal points for traders. A failure to maintain these key thresholds could precipitate additional downward movement. With no scheduled corporate earnings announcements in the coming week, price action will likely remain susceptible to broader market sentiment and positioning adjustments by major institutional investors.

The crucial question facing market participants is whether current pressures represent the deflation of an AI bubble or merely a painful but necessary valuation recalibration within a still-promising growth story.

Ad

Palantir Stock: Buy or Sell?! New Palantir Analysis from May 13 delivers the answer:

The latest Palantir figures speak for themselves: Urgent action needed for Palantir investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from May 13.

Palantir: Buy or sell? Read more here...

Tags: Palantir
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Palantir Stock
AI & Quantum Computing

Palantir Strikes SAP Deal, But NHS Data Storm Clouds Loom Over Growth Story

May 13, 2026
Kontron Stock
Earnings

Kontron’s Record Order Book Masks the Cost of a Painful Restructuring

May 8, 2026
Microsoft Stock
AI & Quantum Computing

Xbox Chief Axes Copilot Plans as Microsoft Pivots From Gaming to Grid-Scale AI

May 7, 2026
Next Post
Unitedhealth Stock

Institutional Investors Boost Stakes in UnitedHealth as Recovery Gains Momentum

Salesforce Stock

Salesforce Faces Data Security Crisis Amid AI Product Launch

Rocket Lab USA Stock

Rocket Lab Shares Tumble as Neutron Delay Overshadows Record Results

Recommended

Murphy Oil Stock

Major Investors Divided on Murphy Oil’s Prospects

9 months ago
Walgreens Stock

Walgreens Implements Drastic Cost-Cutting Measures Under New Ownership

6 months ago
General Electric Stock

GE Aerospace Stock Maintains Impressive Rally Amid Record Performance

7 months ago
Design Therapeutics Stock

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

3 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Synopsys Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Pharma Giants AstraZeneca and GSK Tap Onco-Innovations’ Causal AI to Sharpen Cancer Trial Predictions

Rocket Lab Transforms from Launch Specialist to Full-Scale Space Supplier as Orders Hit $2.2 Billion

With a 1-for-10 Split Behind It, WisdomTree’s Triple-Leveraged Silver Fund Faces Its Toughest Test Yet

Intel’s Nvidia Deal and $5 Billion Vote of Confidence Overshadowed by Market Headwinds

Quantum eMotion’s Taiwan Test Marks the First Step in a Quantum-Safe Energy Pivot

Aixtron’s Optoelectronics Pivot Fuels a Record Order Book, but the Profit Engine Still Needs Time

Trending

IonQ Stock

IonQ Charts New Territory with Urban Planning and Radar as First 256-Qubit System Ships to Cambridge

by Kennethcix
May 13, 2026
0

IonQ is no longer just a quantum computing research house. The company’s first 256-qubit system has left...

Highland Critical Minerals Stock

Highland Critical Minerals Secures C$400,000 for Summer Fieldwork Amid CIRO Probe and 47% Share Price Rout

May 13, 2026
SoftBank Stock

SoftBank Reports Historic ¥5 Trillion Profit, but a Funding Pullback Reveals Creeping Caution

May 13, 2026
Onco-Innovations Stock

Pharma Giants AstraZeneca and GSK Tap Onco-Innovations’ Causal AI to Sharpen Cancer Trial Predictions

May 13, 2026
Rocket Lab USA Stock

Rocket Lab Transforms from Launch Specialist to Full-Scale Space Supplier as Orders Hit $2.2 Billion

May 13, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • IonQ Charts New Territory with Urban Planning and Radar as First 256-Qubit System Ships to Cambridge
  • Highland Critical Minerals Secures C$400,000 for Summer Fieldwork Amid CIRO Probe and 47% Share Price Rout
  • SoftBank Reports Historic ¥5 Trillion Profit, but a Funding Pullback Reveals Creeping Caution

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com